Lv41
702 积分 2021-01-18 加入
A PD-L1xCD3 bispecific nanobody as a novel T-cell engager in treating PD-L1 overexpression melanoma
3小时前
待确认
PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer
5小时前
待确认
Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers
12天前
已完结
Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma
14天前
已完结
A rationally designed bispecific antibody targeting GPC3 and PD-L1 induces tumor-directed immune activation and cytotoxicity
26天前
已完结
Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions
28天前
已完结
Desmoplasia and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma
1个月前
已完结
Key barriers in utilizing advanced T-cell engager strategies on solid tumors
1个月前
已完结
Interleukin-10 and the Interleukin-10 Receptor
1个月前
已完结
Systemic reprogramming of tumour immunity via IL-10-mRNA nanoparticles
1个月前
已完结
皖公网安备34019202002308
